Forescout Addresses Modern SecOps Challenges with Launch of Forescout XDR
Forescout Technologies Inc., the global leader in automated cybersecurity, today unveiled Forescout XDR, to help enterprises better detect, investigate, and respond to the broadest range of advanced threats, across the extended enterprise.
A typical SOC is flooded with 450 alerts per hour1, and analysts waste precious time trying to correlate low fidelity alerts and chasing false positives, often at the expense of focusing on legitimate attacks. Until now, a security operations center’s (SOC) field of view for threat detection and response has excluded critical devices that are increasingly common points of attack, including operational technology (OT), industrial control systems (ICS), building management systems (BMS), and medical and IoT devices. In addition, the technology stack that SecOps teams have had to rely on has made it difficult to respond to these threats in a rapid and comprehensive manner.
“The true value of an XDR solution lies in its ability to ingest telemetry and data from across the entire enterprise: cloud, campus, remote and datacenter environments, and every managed and unmanaged connected device. This is what the X in XDR is all about, after all,” said Justin Foster, CTO, Forescout. “Traditional XDR products lack this capability, or they only leverage data from the vendor’s own EDR or a few other security tools. This significantly limits the flexibility, scalability and effectiveness that an XDR solution must provide.”
Through the advanced application of data science and automation, Forescout XDR generates one high-fidelity alert that truly warrants analyst investigation, from every 50 million logs ingested, per hour2. Because Forescout XDR is vendor- and EDR-agnostic, this ingestion includes data from over 170 security, infrastructure, application, cloud/SaaS and enrichment sources, and dozens of leading vendors. And with over 70 sources of threat intelligence and 1500 verified detection rules and models, and data onboarding included, Forescout XDR customers can be operational within hours, actively detecting, investigating, and responding to threats.
“Forescout XDR, with the breadth and richness of its capabilities, particularly its dashboards and reporting, provides an out-of-the-box solution to SOC challenges that we spent 18-24 months trying to address,” said Samer Mansour, CISO, Panasonic Corporation of North America. “It was easy to deploy, and fully operational in a matter of weeks. And with its tight integration to Forescout’s network security and visibility solutions, and our broader security tech stack, it gives us the ability to exert a lot more control across our IT and OT environments, and further elevate our overall security.”
Seamless integration with Forescout’s industry-leading network access control solution helps ensure that customers can:
- Reduce the attack surface, and the risk of an attack in the first place, by preventing compromised or non-compliant devices from connecting to their networks. This proactive approach to XDR further elevates the effectiveness and performance of a modern SOC.
- Automate response workflows that can immediately touch every managed and unmanaged connected device, across the enterprise. This reduces an attack's blast radius in real-time, allowing proper mitigation or remediation measures to be completed.
Because Forescout XDR has a multi-tenant architecture and supports local data storage while also being able to provide an aggregated global view of threats and SOC performance, it is ideally suited to large enterprises, multi-nationals, organizations with regional SOCs and managed security service providers (MSSPs).
SaaS licensing is based on the total number of endpoints in the enterprise. As such, customers have the flexibility to leverage the data sources needed to fully support the use cases important to them, and help ensure better detection, without concern for escalating or fluctuating costs associated with cloud log storage.
Forescout Technologies, Inc. delivers automated cybersecurity across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types- IT, IoT, OT, IoMT, and cloud environments. The Forescout Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com
Managing cyber risk, together.
“The 2020 State of Security Operations,” Forrester Consulting
Based on aggregate Forescout data from a 1-year period (Dec 2021-2022), across 30 enterprise customers, representing a range of company sizes and industries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005455/en/
Manager of PR
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product8.6.2023 00:12:00 EEST | Press release
RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005794/en/ The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict
IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 23:18:00 EEST | Press release
IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating
Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 22:00:00 EEST | Press release
Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla
Brenus Pharma announces its international Scientific Committee7.6.2023 19:00:00 EEST | Press release
Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active m
Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™7.6.2023 17:00:00 EEST | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005502/en/ CST is a trusted provider of high-quality, rigorously validated antibodies for immunohistochemistry (IHC) that can detect key proteins in a variety of disease states. This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence. With a comprehensive offering of primary rabbit and mous
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom